03.17.17
Dr. Jayant Thatte has been appointed general manager at Crown Bioscience to head up the company's center of excellence in San Diego.
Dr. Thatte is an immunologist with 20 years of research experience in both academia and industry, focusing on cancer, autoimmunity, inflammation and pain. As director of R&D and associate director of operations at Molecular Response, he led the pharmacology team for numerous client projects that increased revenue growth, which ultimately resulted in Crown Bioscience’s acquisition of PDX.
Michael Prosser, vice president of CrownBio's European and North American operations, said, "Dr. Thatte brings established leadership and decades of research experience to the General Manager role. As COO of CrownBio San Diego, Jayant has played a central role in the site's recent growth and success, leading the teams to deliver PDX, syngeneic, cell-line xenograft, and humanized PDX/xenograft platforms, supporting both immuno-oncology and targeted therapy programs for our clients."
Dr. Jean Pierre Wery, chief executive officer of CrownBio, added, "CrownBio invests in our teams' leadership development and succession plans so that dedicated individuals, such as Thatte, are ready to step up and into new roles when needed and to support sustained growth."
Dr. Thatte is an immunologist with 20 years of research experience in both academia and industry, focusing on cancer, autoimmunity, inflammation and pain. As director of R&D and associate director of operations at Molecular Response, he led the pharmacology team for numerous client projects that increased revenue growth, which ultimately resulted in Crown Bioscience’s acquisition of PDX.
Michael Prosser, vice president of CrownBio's European and North American operations, said, "Dr. Thatte brings established leadership and decades of research experience to the General Manager role. As COO of CrownBio San Diego, Jayant has played a central role in the site's recent growth and success, leading the teams to deliver PDX, syngeneic, cell-line xenograft, and humanized PDX/xenograft platforms, supporting both immuno-oncology and targeted therapy programs for our clients."
Dr. Jean Pierre Wery, chief executive officer of CrownBio, added, "CrownBio invests in our teams' leadership development and succession plans so that dedicated individuals, such as Thatte, are ready to step up and into new roles when needed and to support sustained growth."
